Sanofi joins the alpha-synuclein bandwagon, handing Korean biotech $75M for preclinical bispecific
Alpha-synuclein is gaining clout in the growing effort to crush Parkinson’s disease at its roots.
Sanofi became the latest to join the gang late Tuesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
